Impact of Modifications to the Rendering of the Antibiogram on the Prescriptions of Meropenem in Pseudomonas Bacteremia

Launched by UNIVERSITY HOSPITAL, STRASBOURG, FRANCE · Oct 30, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how changes in the way antibiotic sensitivity results are reported can affect the prescription of a specific antibiotic called Meropenem for patients with Pseudomonas infections. In November 2019, a new reporting method was introduced that may have led to doctors prescribing Meropenem too often, even when other effective antibiotics were available. To address this, the hospital changed the reporting again in June 2021, making it less obvious when Pseudomonas bacteria could be treated with Meropenem. The goal of this study is to see how these changes in reporting have influenced doctors’ prescribing habits.

To participate in this trial, you need to be an adult (18 years or older) with a positive blood test for Pseudomonas bacteria that was identified at Strasbourg University Hospital between June 2018 and November 2022. You should also agree to allow your medical data to be used for this research. If you have a strain of Pseudomonas that is resistant to all standard treatments, including Meropenem, or if you cannot provide information about your antibiotic treatment, you would not be eligible to participate. Participants in the study can expect to help researchers understand the effects of these changes and improve antibiotic prescribing practices in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Major subject (≥18 years old)
• • Subject with a positive blood culture result for Pseudomonas spp identified in the microbiology laboratory of Strasbourg University Hospital during the period from June 1, 2018 to November 30, 2022
• • Subject not opposing the reuse of their data for the purposes of this research.
• Exclusion Criteria:
• • Subject having expressed opposition to participating in the study,
• • Pseudomonas spp strain resistant to all first-line beta-lactams (Piperacillin-Tazobactam, Ceftazidime, Céfepime and Aztreonam).
• • Pseudomonas spp strain resistant to Meropenem.
• • Lack of information on the antibiotic treatment undertaken.